Pilatus Biosciences SA
Harnessing Immunometabolism for Cancer Therapy
Shaping the Future of Cancer Treatment and Metabolic Diseases through First-in-class Antibodies and Bifunctional Proteins focusing on Metabolic Checkpoints, reprogramming the immune microenvironment to conquer hard-to-treat cancer and immune-related diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
15.08.2025
Pilatus Biotech to launch first-in-human trials (startupticker.ch)
13.08.2024
Expansion to Taiwan. Pilatus Biosciences Corporation was established in Taiwan.
03.03.2023
Key IP Acquisition. Exclusive license for patent obtained from the University of Lausanne and Ludwig Institute for Cancer Research.
01.01.2023
Global Patent License Secured. Exclusive rights for PLT011 and PLT012 acquired from Elixiron Immunotherapeutics Limited
23.11.2022
Expansion to the USA. Pilatus Biosciences Inc. was established in the USA.
No Jobs
No Awards
Pilatus Biosciences SA
Harnessing Immunometabolism for Cancer Therapy
Website:
www.pilatusbio.com/
Headquarter:
Epalinges
Foundation Date:
January 2022
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug discovery